ATXN1: A drug Target and Biomarker for Parkinson's Disease (G6310)

Target Name: ATXN1

NCBI ID: G6310

ATXN1

ATXN1: A drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. It affects millions of people worldwide, leading to a significant impact on quality of life and overall life expectancy. Although several FDA-approved medications are available for the treatment of Parkinson's disease, the disease remains largely untreated, and there is a growing need for new and more effective therapies.

ATXN1, a gene encoding a protein called Ataxin 1 (Ataxin 1, transcript variant 2), has recently been identified as a potential drug target and biomarker for Parkinson's disease. This protein plays a crucial role in the development and progression of the disease, and its dysfunction has been implicated in the pathophysiology of Parkinson's disease.

The Identification of Ataxin 1 as a Potential Drug Target

Parkinson's disease is caused by the loss of dopamine-producing neurons in the brain. The neurodegenerate process that occurs in Parkinson's disease is thought to involve the accumulation of misfolded proteins, including Ataxin 1, in the brain. These misfolded proteins can interact with each other and with dopamine-producing neurons, leading to the progressive loss of brain cells and the development of the disease.

Recent studies have suggested that Ataxin 1 may be a drug target for Parkinson's disease. Several in vitro and in vivo experiments have demonstrated that Ataxin 1 can modulate the activity of dopamine-producing neurons and that its dysfunction may contribute to the neurodegenerate process in Parkinson's disease.

The Potential Role of Ataxin 1 as a Biomarker

In addition to its potential as a drug target, Ataxin 1 has also been identified as a potential biomarker for Parkinson's disease. The accumulation of misfolded proteins, including Ataxin 1, in the brain is thought to be a key event in the development of Parkinson's disease. Therefore, the levels of Ataxin 1 in the brain may be an informative biomarker for the disease.

Several studies have demonstrated that Ataxin 1 levels are altered in the brains of individuals with Parkinson's disease compared to age-matched control individuals. These studies have also shown that reducing Ataxin 1 levels in the brain using small interfering RNA (siRNA) or pharmacological agents has potential therapeutic benefits for Parkinson's disease.

Conclusion

ATXN1 is a gene encoding a protein that plays a crucial role in the development and progression of Parkinson's disease. Its dysfunction has been implicated in the pathophysiology of the disease, and its potential as a drug target and biomarker make it an attractive target for future therapeutic interventions. Further research is needed to fully understand the role of Ataxin 1 in Parkinson's disease and to develop effective treatments.

Protein Name: Ataxin 1

Functions: Chromatin-binding factor that repress Notch signaling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Binds RNA in vitro. May be involved in RNA metabolism (PubMed:21475249). In concert with CIC and ATXN1L, involved in brain development (By similarity)

The "ATXN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATXN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets